Collaborative research and development of
DDS (drug delivery system) products

Our founder, Yutaka Mizushima (emeritus professor of St. Marianna Medical University, first Parliamentary Secretary for Education, Culture, Sports, Science and Technology), is one of the pioneers in DDS research in Japan, and we are proud that we are a leading company in the DDS field.
Our DDS product, lipo-PGE1 achieved a sales peak of over 50 billion yen in Japan. Our affiliated company, Beijing Tide Pharmaceutical, achieved sales of close to 30 billion yen after successfully launching lipo-PGE1 (Kaishi) in China (ranked the fourth biggest selling pharmaceutical).
Lipo-PGE1 prevents deactivation of PGE1 and allows targeting of PGE1 in an affected site by encapsulation of lipid emulsion, which was first used for a DDS product in the world. Based on this technology, we successfully developed lipid emulsion pharmaceuticals, such as lipo-NSAID. This lipo-NSAID (Kaifen) has also become a major product of Beijing Tide Pharmaceutical with sales of over 20 billion yen.
Subsequently, we have continued to develop the new, world-first DDS technology. For example, PC-SOD, into which we put the most effort, is a DDS product with pharmaceutical activity significantly increased by binding phospholipids to a protein called SOD (super oxide dismutase) (lecithinization). We are the only company that possesses the technology for lecithinizing protein, which can be applied to other kinds of proteins (such as antibodies). If you are interested in our technology, please consult LTT Bio-Pharma.
Moreover, we developed an epoch-making DDS technology called stealth-type nanoparticles. Unlike conventional DDS carriers focusing on either of targeting (selective drug delivery to an affected site) or controlled-release (slowing of drug release), our stealth-type polymeric nanoparticles are the world-first DDS carrier successfully achieving on both of these functions. For example, PGE1-encapsulated nano-particles (nano-PGE1) have more of a pharmacological effect with less dosage and dose frequency than lipo-PGE1 because this accumulates and releases PGE1 on an affected vascular site. This technology can be applied to not only low-molecular compounds but also nucleic acids.
In addition, Hiroshi Kikuchi, PhD, who joined us in October 2018, is a leading researcher in liposome formulation research, had been engaged in research at Daiichi Pharmaceutical (current Daiichi Sankyo) and Eisai. Liposomes are the most common DDS technology for successful clinical application. We hope to be engaged not only in the development of our own liposome products but in collaborative research and development of low-molecular substances and nucleic acids using our expertise in the development of liposome products.
We have additional DDS technologies under development, and they can be applicable to other pharmaceuticals. We are pleased to help in the development of your drugs currently under development, if you hope to improve the efficacy and safety of your drugs using the DDS technology.

Inquiry about collaborative development